U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07811609) titled 'Early Feasibility Study of 3930M Defibrillation Lead Implantation Via the Middle Cardiac Vein in Patients With Tricuspid Valve Regurgitation' on Aug. 27.
Brief Summary: Prospective, single center, early feasibility study designed to evaluate the initial safety and device performance of the Medtronic 3930M Lead when implanted via the Middle Cardiac Vein in patients with Tricuspid Valve Regurgitation
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Defibrillator
Tricuspid Valve Regurgitation
Intervention:
DEVICE: Defibrillator
Required electrical testing for pacing, sensing, impedance, and defibrillation will...